RNXT vs. JMAC, XBIT, ANIX, CRBP, GALT, ARTV, HLVX, VOR, SKYE, and DBVT
Should you be buying RenovoRx stock or one of its competitors? The main competitors of RenovoRx include Maxpro Capital Acquisition (JMAC), XBiotech (XBIT), Anixa Biosciences (ANIX), Corbus Pharmaceuticals (CRBP), Galectin Therapeutics (GALT), Artiva Biotherapeutics (ARTV), HilleVax (HLVX), Vor Biopharma (VOR), Skye Bioscience (SKYE), and DBV Technologies (DBVT). These companies are all part of the "pharmaceutical products" industry.
RenovoRx vs.
Maxpro Capital Acquisition (NASDAQ:JMAC) and RenovoRx (NASDAQ:RNXT) are both small-cap unclassified companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, community ranking, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.
Maxpro Capital Acquisition's return on equity of 0.00% beat RenovoRx's return on equity.
RenovoRx has a consensus price target of $9.00, indicating a potential upside of 847.37%. Given RenovoRx's stronger consensus rating and higher possible upside, analysts plainly believe RenovoRx is more favorable than Maxpro Capital Acquisition.
Maxpro Capital Acquisition has a beta of 0.01, suggesting that its share price is 99% less volatile than the S&P 500. Comparatively, RenovoRx has a beta of 1.1, suggesting that its share price is 10% more volatile than the S&P 500.
73.2% of Maxpro Capital Acquisition shares are owned by institutional investors. Comparatively, 3.1% of RenovoRx shares are owned by institutional investors. 19.3% of Maxpro Capital Acquisition shares are owned by insiders. Comparatively, 7.1% of RenovoRx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
In the previous week, RenovoRx had 3 more articles in the media than Maxpro Capital Acquisition. MarketBeat recorded 4 mentions for RenovoRx and 1 mentions for Maxpro Capital Acquisition. Maxpro Capital Acquisition's average media sentiment score of 0.67 beat RenovoRx's score of 0.22 indicating that Maxpro Capital Acquisition is being referred to more favorably in the media.
RenovoRx received 9 more outperform votes than Maxpro Capital Acquisition when rated by MarketBeat users.
Summary
RenovoRx beats Maxpro Capital Acquisition on 6 of the 11 factors compared between the two stocks.
Get RenovoRx News Delivered to You Automatically
Sign up to receive the latest news and ratings for RNXT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
RenovoRx Competitors List
Related Companies and Tools
This page (NASDAQ:RNXT) was last updated on 3/4/2025 by MarketBeat.com Staff
Free RNXT Stock Alerts